AHUS membrane protein-associated disorders are suspected to belong to the field of blood tumours. Clinical manifestations are complex and often involve multi-system congestion. Early identification and standardised clinical care are essential for improving prognosis.
The diagnosis of this disease requires a combination of clinical manifestations, imaging inspections, laboratory testing and pathological activation. The platform can assist in matching the needs of a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumor diseases have been significantly improved.
Treatment needs to be closely monitored for efficacy and adverse reactions, adjusted in a timely manner according to changes in the disease. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of aHUS membrane protein. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.